The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes
When clinically and payer-relevant outcomes from the SELECT trial are included in calculations of NNT, semaglutide was associated with greater risk reductions and lower estimates of NNT than for the primary endpoint alone. Our findings suggest that including the broader effects of semaglutide beyond the primary trial endpoint recognizes additional value to stakeholders.
Authors
- A. Michael Lincoff (ORCID: https://orcid.org/0000-0001-8175-2121)
- Geraint Roberts (ORCID: https://orcid.org/0000-0003-2006-4581)
- Ruben Vale (ORCID: https://orcid.org/0000-0002-6640-1945)
- Jorge Plutzky (ORCID: https://orcid.org/0000-0002-7194-9876)
- Christopher Lübker (ORCID: https://orcid.org/0000-0003-3220-801X)
- Emil Nørtoft (ORCID: https://orcid.org/0000-0002-1450-8214)
- Scott S. Emerson (ORCID: https://orcid.org/0000-0002-2695-0165)
- Jens M. Tarp
- Jigish Bhavsar (ORCID: https://orcid.org/0000-0002-0613-3571)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Novo Nordisk (Denmark) (DK)
- University of Washington (US)
- Cleveland Clinic Lerner College of Medicine (US)
- Novo Nordisk (United States) (US)
- Health Economics and Outcomes Research (United Kingdom) (GB)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-03-29
- DOI
- https://doi.org/10.1007/s12325-025-03176-w
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59
Funders
- Novo Nordisk